Hope & Expectancy in Placebo and Nocebo Effects | Irving Kirsch

Added:

Classical Conditioning and Non-Cognitive Mechanisms

While Irving Kirsch's Response Expectancy Theory emphasizes conscious cognitive expectations and hope, a major alternative perspective argues that placebo and nocebo responses are primarily driven by classical conditioning and unconscious physiological processes. Proponents of this view, supported by researchers like Fabrizio Benedetti, demonstrate that physiological systems (such as the immune and endocrine systems) can be conditioned to respond to neutral stimuli without requiring conscious belief or expectation. For example, repeatedly pairing an active drug with a placebo can eventually elicit the drug's physiological effect through the placebo alone, even when administered unconsciously. Furthermore, the success of 'open-label placebos'—where patients knowingly take an inactive substance and still improve—challenges the notion that a conscious expectation of clinical benefit is necessary. This perspective suggests that the placebo effect is often an automatic, embodied Pavlovian response rather than a purely cognitive phenomenon driven by hope.

Understanding the fundamental definitions of the placebo effect (beneficial responses to inert treatments) and the nocebo effect (adverse reactions to inert treatments).
Familiarity with classical conditioning and cognitive expectancy theory, specifically how psychological anticipation influences physiological responses.
Basic knowledge of clinical trial methodology, including the purpose of control groups, blinding, and randomized controlled trials (RCTs).
An introductory understanding of the psychology and neurobiology of pain perception, particularly how subjective experiences of pain can be modulated by cognitive states.
Exploring Irving Kirsch's influential and controversial meta-analyses on the efficacy of antidepressants and the high placebo response rate in depression treatment.
Investigating the neurobiological pathways of expectancy, such as the release of endogenous opioids and dopamine during placebo analgesia.
Examining the concept and clinical efficacy of 'open-label placebos'—where patients knowingly take a placebo but still experience therapeutic benefits.
Analyzing the ethical and practical implications for medical practice, including how clinician communication and patient-provider relationships can minimize nocebo effects and maximize healing.
209 views1likes32:30@SFB-TRR_289Original Release: 2023-02-11

Placebo and nocebo effects are primarily driven by treatment expectancies rather than stimulus expectancies, with hope (defined as desire) and expectation working together to produce therapeutic or adverse effects; research demonstrates that manipulating treatment expectancies produces stronger placebo responses than manipulating stimulus expectancies, and that measuring expectancies prospectively rather than retroactively yields more accurate results, while avoiding dichotomization of continuous data improves research validity.